BIH-Technologieplattform Genomik

Diese Seite ist zurzeit nur auf Englisch verfügbar.

The recent introduction of novel sequencing technology (NGS) has revolutionized genomic research. As BIH Core Facility Genomics, our labs at two locations (Campus Buch and Campus Rudolf-Virchow) will provide NGS support for BIH Groups. The services ranges from whole genome (re)sequencing, targeted genome sequencing, transcriptome sequencing to various epigenomic profilings. Apart from offering 'just' the services to the institute as a core facility, we have developed various NGS-based genomic assays.

Please find more information about the so called Scientific Genomics Platform - Laboratory of Functional Genomics, Nutrigenomics and Systems Biology here:

A recent paper in Nature shows what the PacBio sequencer can do. Tracing cell development with barcodes

Since April 2017 the bioinformatician Tomasz Zemojtel is working at the Berlin Insitute of Health, where he will establish the second core facility genomics. We talked with him about his work and future plans.

Please find more information about his core facility here.

BIH Genomics Core Facility offers liquid biopsy service

Liquid biopsy holds the promise for cancer patient stratification, prediction of treatment response and cancer resistance with the goal of changing the clinical focus to tailored treatments. The BIH genomics platform offers as one of the first institutions worldwide a novel non-invasive liquid biopsy assay based on the detection of circulating tumor DNA (ctDNA) representing the genetic profile of tumors combined with the power of next generation sequencing. The AVENIO ctDNA analysis kits will be used for identifying guideline-related biomarkers, emerging biomarkers identified in clinical studies, and to longitudinally monitor tumor burden for different malignancies. Future applications will include screenings leading to early cancer detection.

For more information, do not hesitate to contact Dr. Tomasz Zemojtel:


Leitung Campus Buch
Dr. Sascha Sauer
Leitung Campus Mitte
Dr. Tomasz Zemojtel




Dr. Sascha Sauer

Dr. Tomasz Zemojtel

Prof. Norbert Hübner: Forschungsgruppe "Genetics and Genomics of Cardiovascular Diseases"

Prof. Angelika Eggert: Direktorin Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie

Prof. Ana Pombo: Leiterin Forschungsgruppe "Epigenetische Regulation und Chromatinstruktur"

Prof. Michael Hummel: Experimentelle Hämatopathologie, Leiter ZeBanC

Prof. Nikolaus Rajewsky: Direktor BIMSB, Research Group "Systems Biology of Gene Regulatory Elements"

Prof. Ulrich Keilholz: Direktor des Charité Comprehensive Cancer Center; Prof. für Hämatologie und Onkologie


Prof. Heiko Krude: Co-Leiter des Berliner Centrums für Seltene Erkrankungen